Literature DB >> 23506478

The oncolytic activity of Newcastle disease virus in clear cell renal carcinoma cells in normoxic and hypoxic conditions: the interplay between von Hippel-Lindau and interferon-β signaling.

Wei-Choong Ch'ng1, Eric J Stanbridge, Khatijah Yusoff, Norazizah Shafee.   

Abstract

Viral-mediated oncolysis is a promising cancer therapeutic approach offering an increased efficacy with less toxicity than the current therapies. The complexity of solid tumor microenvironments includes regions of hypoxia. In these regions, the transcription factor, hypoxia inducible factor (HIF), is active and regulates expression of many genes that contribute to aggressive malignancy, radio-, and chemo-resistance. To investigate the oncolytic efficacy of a highly virulent (velogenic) Newcastle disease virus (NDV) in the presence or absence of HIF-2α, renal cell carcinoma (RCC) cell lines with defective or reconstituted wild-type (wt) von Hippel-Lindau (VHL) activity were used. We show that these RCC cells responded to NDV by producing only interferon (IFN)-β, but not IFN-α, and are associated with increased STAT1 phosphorylation. Restoration of wt VHL expression enhanced NDV-induced IFN-β production, leading to prolonged STAT1 phosphorylation and increased cell death. Hypoxia augmented NDV oncolytic activity regardless of the cells' HIF-2α levels. These results highlight the potential of oncolytic NDV as a potent therapeutic agent in the killing of hypoxic cancer cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23506478      PMCID: PMC3708626          DOI: 10.1089/jir.2012.0095

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  47 in total

Review 1.  Hypoxia-inducible factors in physiology and medicine.

Authors:  Gregg L Semenza
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582

2.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

3.  Newcastle disease virus selectively kills human tumor cells.

Authors:  K W Reichard; R M Lorence; C J Cascino; M E Peeples; R J Walter; M B Fernando; H M Reyes; J A Greager
Journal:  J Surg Res       Date:  1992-05       Impact factor: 2.192

4.  Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines.

Authors:  Sateesh Krishnamurthy; Toru Takimoto; Ruth Ann Scroggs; Allen Portner
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

Review 5.  The suppressors of cytokine signalling (SOCS).

Authors:  B T Kile; W S Alexander
Journal:  Cell Mol Life Sci       Date:  2001-10       Impact factor: 9.261

6.  Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.

Authors:  Han Hsi Wong; Nicholas R Lemoine; Yaohe Wang
Journal:  Viruses       Date:  2010-01       Impact factor: 5.818

Review 7.  The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2008-10-16       Impact factor: 60.716

8.  Replication and cytopathic effect of oncolytic vesicular stomatitis virus in hypoxic tumor cells in vitro and in vivo.

Authors:  John H Connor; Christine Naczki; Costas Koumenis; Douglas S Lyles
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

Review 9.  HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression.

Authors:  Brian Keith; Randall S Johnson; M Celeste Simon
Journal:  Nat Rev Cancer       Date:  2011-12-15       Impact factor: 60.716

10.  Effects of newcastle disease virus strains AF2240 and V4-UPM on cytolysis and apoptosis of leukemia cell lines.

Authors:  Aied M Alabsi; Siti Aishah Abu Bakar; Rola Ali; Abdul Rahman Omar; Mohd Hair Bejo; Aini Ideris; Abdul Manaf Ali
Journal:  Int J Mol Sci       Date:  2011-11-30       Impact factor: 5.923

View more
  18 in total

1.  Human renal carcinoma cells respond to Newcastle disease virus infection through activation of the p38 MAPK/NF-κB/IκBα pathway.

Authors:  Wei-Choong Ch'ng; Noraini Abd-Aziz; Meng-Hua Ong; Eric J Stanbridge; Norazizah Shafee
Journal:  Cell Oncol (Dordr)       Date:  2015-05-01       Impact factor: 6.730

Review 2.  The application of oncolytic viruses in cancer therapy.

Authors:  Yang Gao; Yan Wu; Tian Huan; Xiaoyan Wang; Jun Xu; Qinggang Xu; Feng Yu; Haifeng Shi
Journal:  Biotechnol Lett       Date:  2021-08-26       Impact factor: 2.461

Review 3.  Development of Molecular Mechanisms and Their Application on Oncolytic Newcastle Disease Virus in Cancer Therapy.

Authors:  Fang Huang; Chuanjing Dai; Youni Zhang; Yuqi Zhao; Yigang Wang; Guoqing Ru
Journal:  Front Mol Biosci       Date:  2022-07-04

Review 4.  Oncolytic virotherapy for urological cancers.

Authors:  Zahid Delwar; Kaixin Zhang; Paul S Rennie; William Jia
Journal:  Nat Rev Urol       Date:  2016-05-24       Impact factor: 14.432

5.  Bortezomib attenuates HIF-1- but not HIF-2-mediated transcriptional activation.

Authors:  Noraini Abd-Aziz; Eric J Stanbridge; Norazizah Shafee
Journal:  Oncol Lett       Date:  2015-07-29       Impact factor: 2.967

6.  Newcastle disease virus degrades HIF-1α through proteasomal pathways independent of VHL and p53.

Authors:  Noraini Abd-Aziz; Eric J Stanbridge; Norazizah Shafee
Journal:  J Gen Virol       Date:  2016-10-06       Impact factor: 3.891

Review 7.  Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients.

Authors:  Volker Schirrmacher
Journal:  Int J Mol Sci       Date:  2017-05-20       Impact factor: 5.923

8.  Intratumoral Virotherapy with Wild-Type Newcastle Disease Virus in Carcinoma Krebs-2 Cancer Model.

Authors:  Kseniya S Yurchenko; Alexandra V Glushchenko; Marina A Gulyaeva; Yuhai Bi; Jianjun Chen; Weifeng Shi; Lyubov S Adamenko; Alexander M Shestopalov
Journal:  Viruses       Date:  2021-03-25       Impact factor: 5.048

9.  Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host.

Authors:  Philippe Fournier; Volker Schirrmacher
Journal:  Biology (Basel)       Date:  2013-07-02

Review 10.  Multimodal cancer therapy involving oncolytic newcastle disease virus, autologous immune cells, and bi-specific antibodies.

Authors:  Volker Schirrmacher; Philippe Fournier
Journal:  Front Oncol       Date:  2014-09-11       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.